Lehrstuhl für Pharmakologie und Toxikologie

Retronasal olfactory testing in early diagnosed and suspected COVID-19 patients: a 7-week follow-up study (2021) Prem B, Liu DT, Besser G, Renner B, Mueller CA Journal article A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions (2021) Mueller CA, Winter M, Renner B Journal article Assessment of odor hedonic perception: the Sniffin’ sticks parosmia test (SSParoT) (2020) Liu DT, Welge-Lüssen A, Besser G, Mueller CA, Renner B Journal article Odor Mixtures in Identification Testing Using Sniffin’ Sticks: The SSomix Test (2020) Liu DT, Besser G, Lang M, Sharma G, Pablik E, Renner B, Mueller CA Journal article Radiological Markers of the Olfactory Cleft: Relations to Unilateral Orthonasal and Retronasal Olfactory Function (2020) Liu DT, Schwarz-Nemec U, Renner B, Mueller CA, Besser G Journal article Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) (2020) Rech J, Schenker H, Tascilar K, Hagen M, Kleyer A, Simon D, Mendez LV, et al. Conference contribution The hyperpolarization-activated cyclic nucleotide-gated 4 channel as a potential anti-seizure drug target (2020) Kharouf Q, Phillips AM, Bleakley LE, Morrisroe E, Oyrer J, Jia L, Ludwig A, et al. Journal article CENTRAL NERVOUS SYSTEM PAIN RESPONSE AND COMPONENTS OF DISEASE ACTIVITY IN RA PATIENTS AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO: A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Schenker H, Rech J, Tascilar K, Hagen M, Schoenau V, Sergeeva M, Selvakumar M, et al. Conference contribution PREDICTION OF RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT BY FUNCTIONAL MRI OF THE BRAIN: AN INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (PRECEPRA) (2020) Rech J, Tascilar K, Schenker H, Sergeeva M, Selvakumar M, Konerth L, Prade J, et al. Conference contribution LONGITUDINAL CHANGE IN THE CENTRAL NERVOUS SYSTEM PAIN RESPONSE AFTER TREATMENT WITH CERTOLIZUMAB OR PLACEBO. A POST-HOC ANALYSIS FROM THE PRECEPRA TRIAL (2020) Rech J, Tascilar K, Schenker H, Hagen M, Sergeeva M, Selvakumar M, Konerth L, et al. Conference contribution